Safety of Intravenous Lidocaine Infusions

Safety of Intravenous Lidocaine Infusions for Chronic Neuropathic Pain

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01091935

Enrollment

Registered

2010-03-24

Start date

2009-06-30

Completion date

2010-01-31

Last updated

2010-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic Pain

Keywords

Lidocaine,Intravenous Infusions,Neuropathic Pain,Side Effects

Brief summary

The purpose of this study is to prospectively determine the side effects profile in adults with neuropathic pain receiving intravenous infusions of lidocaine 5 mg per kg of lean body weight, infused over 45 minutes.

Detailed description

Eligibility Criteria: Adults \> 18 yrs with chronic central or peripheral neuropathic pain at the St Joseph's Health Care Pain Clinic between June and December 2009. Outcome measures: All side effects spontaneously reported. Sedation, nausea, dizziness by Visual Analog Score Q 15 minutes; hemodynamic data q 5 minutes during and after infusion for 30 minutes. Daily diary of side effects and Visual Analogue score of Pain for 7 days post-infusion.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adult outpatients \> 18 years \< 80 years diagnosed with chronic neuropathic pain

Exclusion criteria

* Unable to provide informed consent * Unable to speak and understand English * Liver, kidney, or cardiac failure * Allergy to Lidocaine

Countries

Canada

Outcome results